Last reviewed · How we verify

NCT04555174: BIOFLOW-VIII

BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry

Active, enrolled Last updated 21 June 2024
What this trial tests

trial testing Orsiro Mission DES in Coronary Artery Disease in 872 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
25 September 2020
Primary endpoint
18 January 2023
19 February 2027

Quick facts

Lead sponsorBiotronik AG
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment872
Start date25 September 2020
Primary completion18 January 2023
Estimated completion19 February 2027
Sites41 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Biotronik AG

Who can join

18 and older, any sex, with Coronary Artery Disease or Myocardial Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BIOFLOW-VIII registry is a post-market clinical evaluation of the Orsiro Mission stent in subjects requiring coronary revascularization with Drug Eluting Stents (DES).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Biotronik AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04555174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing